---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-055484"
form_type: "8-K"
ticker: "STTK"
cik: "0001680367"
company_name: "Shattuck Labs, Inc."
filed_at: "2026-08-11T10:59:00+00:00"
generated_at: "2026-08-11T11:00:13.712921+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Shattuck Labs Q2 net loss widens to $15.2M; cash $208M; SL-325 Phase 1 positive

## Summary
- Q2 2026 net loss $15.2M ($0.12/sh) vs $12.5M ($0.24/sh) in Q2 2025; R&D $11.7M, G&A $4.5M.
- Cash, equivalents and short-term investments $208.3M at 6/30/26, expected to fund operations into 2029.
- SL-325 Phase 1: 3.7% ADA, >3-month DR3 blockade at ≥1mg/kg, favorable safety, no DR3 agonism.
- RECEPTIVE-CD1 Phase 2b Crohn's starts Q3 2026: ~232 pts, primary endpoint endoscopic response at 12 wks, data 1H 2028.
- SL-846 bispecific (DR3 x IL-23R) in IND-enabling tox; Phase 1 healthy volunteer trial expected 2027; poster at UEGW Oct 2026.

## SEC filing metadata
- accession: 0001628280-26-055484
- form_type: 8-K
- ticker: STTK
- cik: 0001680367
- company_name: Shattuck Labs, Inc.
- filed_at: 2026-08-11T10:59:00+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1680367/000162828026055484/0001628280-26-055484-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1680367/000162828026055484/sttk-20260811.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-055484
- JSON: https://secwatch.observer/filing/0001628280-26-055484.json
- Plain text: https://secwatch.observer/filing/0001628280-26-055484.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.